Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Fuchs

Showing results (271-280 of 373) with videos related to

Pageof 38
Sort By:
The Lancet. Haematology|March 26, 2021
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)Sarah Gillessen, Annette Plütschow, Michael Fuchs, et al.
International Journal of Molecular Sciences|November 24, 2019
CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid LeukemiaTobias Gluexam, Alexander M Grandits, Angela Schlerka, et al.
International Journal of Radiation Oncology, Biology, Physics|April 17, 2024
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study GroupJohannes Rosenbrock, Helen Kaul, Michael Oertel, et al.
Hepatology Communications|February 5, 2024
The RIVET RCT: Rifamycin SV MMX improves muscle mass, physical function, and ammonia in cirrhosis and minimal encephalopathyJasmohan S Bajaj, Andrew Fagan, Edith A Gavis, et al.
JAMA Oncology|February 5, 2026
BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin LymphomaJustin Ferdinandus, Horst Müller, Janina Jablonski, et al.
The Lancet. Oncology|September 11, 2016
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study GroupStefanie Kreissl, Horst Mueller, Helen Goergen, et al.
Gastroenterology|September 21, 2010
Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathyJasmohan S Bajaj, Douglas M Heuman, James B Wade, et al.
Leukemia|August 19, 2021
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study GroupCarla Damaschin, Helen Goergen, Stefanie Kreissl, et al.
Journal of Hepatology|May 14, 2013
Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosisVishwadeep Ahluwalia, James B Wade, Leroy Thacker, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 26, 2019
Alterations in Skin Microbiomes of Patients With CirrhosisJasmohan S Bajaj, Andrew Fagan, Masoumeh Sikaroodi, et al.
Pageof 38

Showing results (271-280 of 373) with videos related to

Sort By:
Pageof 38
The Lancet. Haematology|March 26, 2021
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)Sarah Gillessen, Annette Plütschow, Michael Fuchs, et al.
International Journal of Molecular Sciences|November 24, 2019
CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid LeukemiaTobias Gluexam, Alexander M Grandits, Angela Schlerka, et al.
International Journal of Radiation Oncology, Biology, Physics|April 17, 2024
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study GroupJohannes Rosenbrock, Helen Kaul, Michael Oertel, et al.
Hepatology Communications|February 5, 2024
The RIVET RCT: Rifamycin SV MMX improves muscle mass, physical function, and ammonia in cirrhosis and minimal encephalopathyJasmohan S Bajaj, Andrew Fagan, Edith A Gavis, et al.
JAMA Oncology|February 5, 2026
BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin LymphomaJustin Ferdinandus, Horst Müller, Janina Jablonski, et al.
The Lancet. Oncology|September 11, 2016
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study GroupStefanie Kreissl, Horst Mueller, Helen Goergen, et al.
Gastroenterology|September 21, 2010
Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathyJasmohan S Bajaj, Douglas M Heuman, James B Wade, et al.
Leukemia|August 19, 2021
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study GroupCarla Damaschin, Helen Goergen, Stefanie Kreissl, et al.
Journal of Hepatology|May 14, 2013
Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosisVishwadeep Ahluwalia, James B Wade, Leroy Thacker, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 26, 2019
Alterations in Skin Microbiomes of Patients With CirrhosisJasmohan S Bajaj, Andrew Fagan, Masoumeh Sikaroodi, et al.
Pageof 38